Adrianzen Herrera D, Pradhan K, Snyder R, Karanth S, Janakiram M, Mantzaris I, Braunschweig I, Budhathoki A, Shah UA, Verma AK, Murthy SB, Shastri A. Myelodysplastic syndromes and the risk of cardiovascular disease in older adults: A SEER-Medicare analysis. Leukemia. 2020 Jun;34(6):1689-93. doi: 10.1038/s41375-019-0673-8
Graham J, Earnshaw S, Lim J, Luthra R, Borker R. Cost-effectiveness of afatinib versus erlotinib in the first-line treatment of patients with metastatic non-small cell lung cancer with EGFR Exon 19 deletion mutations. JCP. 2016 May;2(4):31-9.
Henk HJ, Kaye JA, Rothman KJ, Becker LK, Legg JC, Li X. Variation by age in neutropenic complications among patients with cancer receiving chemotherapy. Community Oncol. 2013 Jan 1;10(1):16-26.
Oglesby A, Sherif B, Odom D, Leahy M, Qian Y. Time and costs associated with preparing and administering zoledronic acid in patients with breast or prostate cancer and metastatic bone disease. Community Oncol. 2009 Nov 1;6(11):494-502.
Buchanan A, Sugg Skinner C, Calingaert B, Schildkraut J, King R, Marcom K. Cancer genetic counseling in rural North Carolina oncology clinics: program establishment and patient characteristics. Community Oncol. 2009;6(2):70-7.